1Abbruzzese JL Therapeutic Principles of Gastrointestinal Neoplasia emerging Therapies: Vaccines. In: Gastrointestinal Oncology\. UK: Oxford University Press, 2003.102-106.
2Rosen L. Antiangiogenic strategies and agents in clinical trials[J]. Oncologist,2000,5(suppl 1):20-27.
3Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo[J]. Nature, 1993,362:841-844.
4Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus .uorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2003, 21: 60-65.
5Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC); results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-.uorouracil, leucovorin) as .rst-line therapy in subjects with metastatic CRC[J]. Proc Am Soc Clin Oncol, 2003, 22,A3646.
6Rothenberg M L, Berlin J D, Cropp G F, et al. Phase I/II study of SU5416 in combination with irinotecan/5-FU/LV (IFL) in patients with metastatic colorectal cancer[J]. Proc Am Soc Clin Oncol, 2001,20:75a. Abstract 298.
7Rosen P, Amado R, Hecht J, et al. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer[J]. Proc Am Soc Clin Oncol,2000,19:Abstract 5D.
8Raymond E, Faivre S, Vera K, et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol[J] 2003,22:192. Abstract 769.
9Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy[J]. Endocr Relat Cancer, 2001,8:3-9.
10Baselga J, Albanell J. Epithelial growth factor receptor interacting agents[J]. Hematol Oncol Clin North Am. 2002,16:1041-1063.
